GLP-1 receptor agonist treatment and cardiovascular outcomes following aortic valve replacement: a nationwide observational study
- Design
- Retrospective cohort · 292 participants · Hard outcome
- Match to healthy normal-weight adults aged 55–75
- Partial matchPARTIAL: patients were selected for severe aortic stenosis undergoing valve replacement in Western Denmark; age, BMI, obesity and diabetes status are not reported, though the background frames GLP-1 benefit in diabetes, overweight and obesity.
- Could weight loss explain it?
- PossiblyThe abstract reports no weight, HbA1c or blood-pressure change and no analysis separating them from a drug effect; propensity score matching balanced baseline confounding only.
- Study tier
- Study tier 3LOW: single nationwide observational cohort with propensity matching and 292 analysed patients; the observational design caps the tier.
- Assessment
- Version 4 · Two reviewers differed; settled by a recorded ruling · Oct 19, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
This Danish registry study looked at patients with severe aortic stenosis who had their aortic valve replaced, comparing 292 propensity-matched patients with and without GLP-1 receptor agonist treatment. Over a mean follow-up of 4.8±2.4 years, treatment was linked to a lower risk of the combined outcome of death, heart failure hospitalization or valve reoperation (HR 0.69, 95%CI 0.50-0.96) and of death alone (HR 0.66); no outcome was reported as null. Only 292 of 5259 eligible patients were matched and the study is observational, so these are associations, not proof of benefit.
01Findings
What the study reported
- Drugs
- Glp-1 receptor agonists
- Dose
- various
- Comparator
- propensity score-matched controls
- Primary outcome
- composite of all-cause mortality, heart failure hospitalization or aortic valve reoperation
- Effect
- Primary composite HR 0.69 (95%CI 0.50-0.96, p=0.029); all-cause mortality HR 0.66 (95%CI 0.46-0.95, p=0.025); heart failure hospitalization HR 0.67 (95%CI 0.48-0.93, p=0.018); aortic valve reoperation HR 0.69 (95%CI 0.49-0.98, p=0.037); no null outcome reported
- 95% confidence interval
- 95%CI 0.50-0.96 (primary composite)
- P value
- p=0.029 (primary composite)
- Follow-up
- mean 4.8±2.4 years
- Adverse events
- not reported in abstract
- Limitations
- Observational registry cohort with a small matched sample (292 of 5259 eligible patients), so residual confounding and imprecision are possible; the abstract does not say why patients received GLP-1 receptor agonists.
Who was studied
- Obesity status
- not reported in abstract
- Diabetes status
- not reported in abstract
- Cvd status
- severe aortic stenosis required (undergoing valve replacement)
- Ckd status
- not reported in abstract
- Baseline condition
- severe aortic stenosis undergoing TAVI or SAVR
- Sample size
- 292
- Inclusion exclusion
- consecutive patients with severe aortic stenosis undergoing TAVI or SAVR in Western Denmark, January 2016 to April 2022
Study quality details
- Study design
- Retrospective cohort
- Sample size
- 292
- Randomization
- no
- Blinding
- n/a
- Comparator
- propensity score-matched controls
- Follow up duration
- mean 4.8±2.4 years
- Outcome type
- hard
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- PARTIAL
- Statistical precision
- CIs reported; 292 matched patients; event counts not stated
- Risk of bias
- not assessed
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- not reported in abstract
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
[BACKGROUND] GLP-1 receptor agonists reduce major adverse cardiovascular events among patients with diabetes, overweight, and obesity. Whether these benefits extend to patients undergoing aortic valve replacement (AVR) for severe aortic stenosis (AS) remains unknown. Thus, we investigated the association between GLP-1 receptor agonist treatment and cardiovascular outcomes after AVR. [METHODS] Nationwide population-based cohort study including consecutive patients with severe AS undergoing TAVI or SAVR in Western Denmark between January, 2016 and April, 2022. Patients were followed until death, emigration, crossover, or end of follow up on May 12, 2026. Propensity score-matching was performed to balance confounding. The primary outcome was a composite of all-cause mortality, heart failure hospitalization, or aortic valve reoperation. Secondary outcomes included all-cause mortality, heart failure hospitalization, aortic valve reoperation, with analyses accounting for the competing risk of death. [RESULTS] Among 5259 eligible patients undergoing AVR, 292 propensity score-matched patients were included in the final analyses. During a mean follow up of 4.8±2.4 years, GLP-1 receptor agonist treatment was associated with a lower risk of the primary composite outcome compared with controls (HR 0.69, 95%CI 0.50-0.96, p=0.029). GLP-1 receptor agonist treatment was also associated with lower risk of all-cause mortality (HR 0.66, 95%CI 0.46-0.95, p=0.025). In competing risk analyses accounting for death, lower risks were observed for heart failure hospitalization (HR 0.67, 95%CI 0.48-0.93, p=0.018), and aortic valve reoperation (HR 0.69, 95%CI 0.49-0.98, p=0.037). [CONCLUSION] Treatment with GLP-1 receptor agonists was associated with lower risk of cardiovascular outcomes including mortality following AVR among patients with severe AS.